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Patrick Rowea, Tim Farleya, Alexandre Peregoudova, Gilda Piaggiob, Simone Boccarda,
Sihem Landoulsic, Olav Meirikd,⁎ for the IUD
Research Group of the UNDP/UNFPA/WHO/World Bank Special Programme of Research,
Development and Research Training in Human Reproduction1
aUNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Geneva, Switzerland
bMedical Statistics Department, London School of Hygiene and Tropical Medicine, London, UK
cDepartment of Reproductive Health and Research, World Health Organization, Geneva, Switzerland
dInstituto Chileno de Medicina Reproductiva (ICMER), Santiago, ChileWe wish to make the following corrections to our article
in the June 2016 issue of Contraception [1].
Page 498, first sentence of the Abstract should read:
To compare rates of unintended pregnancy, method
continuation and reasons for removal among women
using the 52-mg levonorgestrel (daily release 20 microg)
intrauterine device (LNG-IUD) or the copper T 380 A
IUD (TCu380A).
Page 500, left column, first paragraph, first sentence should
read: The trial was initially planned for at least 10 years of
follow-up of use of the IUDs.DOI of original article: http://dx.doi.org/10.1016/j.contraception.2016.02.024.
⁎ Corresponding author.
E-mail address: olav.meirik@gmx.com (O. Meirik).
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should read: The rate of discontinuation due to increased
bleeding is slightly higher for the LNG-IUD than for the
TCu380A in Chinese centres, while in non-Chinese centres,
this pattern is reversed.
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